RASGEF1C methylation for the distinguishment and classification of benign and malignant thyroid tumors
Our study revealed RASGEF1C methylation as a promising biomarker for distinguishing and classifying benign and malignant thyroid tumors and even provided epigenetic evidence for the inflammatory-cancer transformation. Nevertheless, the limitation of tissue-based biomarkers should be well noted, and the development of more accessible biomarkers warrants further exploration in the future.
Authors
- Xuandong Huang
- Haixia Huang (ORCID: https://orcid.org/0000-0001-8481-7277)
- Wenjing Yu (ORCID: https://orcid.org/0000-0002-6833-3528)
- Mengxia Li (ORCID: https://orcid.org/0000-0003-4443-740X)
- Rongxi Yang (ORCID: https://orcid.org/0000-0002-6655-1986)
- Junjie Li (ORCID: https://orcid.org/0000-0003-2152-6952)
- Yi Zhang (ORCID: https://orcid.org/0000-0001-5388-1276)
- Lun Zhu
- Yifen Zhang
- Chenxia Jiang
- Yifei Yin (ORCID: https://orcid.org/0000-0002-0806-221X)
Institutions
- Nanjing University of Chinese Medicine (CN)
- Xuzhou Medical College (CN)
- Second People’s Hospital of Huai’an (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1186/s13148-025-01931-y
- Citations
- 1
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Government of Jiangsu Province
- Nanjing Medical University